Fig. 3

Changes in days of acute headache medication use over Weeks 1–12 in eptinezumab-treated ≥ 75% migraine responders in (A) PROMISE-1 and (B) PROMISE-2 and in ≥ 50–< 75% migraine responders in (C) PROMISE-1 and (D) PROMISE-2. Analyses for each medication are limited to patients who used that medication during the 28-day baseline period. A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. CM, chronic migraine; EM, episodic migraine; Epti, eptinezumab.